This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| CIME Nanotech | |
|---|---|
| Name | CIME Nanotech |
| Type | Private |
| Industry | Nanotechnology |
| Founded | 2009 |
| Founder | Dr. Elena Morozov |
| Headquarters | Geneva, Switzerland |
| Key people | Dr. Elena Morozov; Prof. Mateo Alvarez; Dr. Aisha Khan |
| Products | Nanomaterials; nanoelectronics; therapeutics; sensors |
| Revenue | Confidential |
| Employees | 420 (2025) |
CIME Nanotech is a multinational company specializing in nanoscale materials, devices, and translational nanobiotechnology. Founded in 2009, it develops engineered nanoparticles, nanoelectronics, and nanosensors for use across pharmaceutical, electronics, energy, and environmental sectors. The company is known for combining academic collaborations, commercial partnerships, and proprietary fabrication platforms to move bench-scale research toward regulatory approval and market deployment.
CIME Nanotech was established in Geneva, following research transitions between laboratories at University of Cambridge, École Polytechnique Fédérale de Lausanne, Massachusetts Institute of Technology, and Swiss Federal Institute of Technology Zurich. Early funding and seed investment drew on venture rounds connected to investors in Silicon Valley, London, and Zurich, while initial intellectual property built on patents originating from collaborations with Max Planck Society and CNRS. During the 2010s the company expanded through technology licensing agreements with Roche, Novartis, and spin-out programs associated with Imperial College London and Harvard University. Strategic hires included researchers from IBM Research, Intel, and Bell Labs, supporting transitions into nanoelectronics and nanoscale fabrication. By the late 2010s CIME established production partnerships with manufacturers in South Korea, Taiwan, and Germany and announced translational programs aligned with regulatory pathways used by European Medicines Agency and U.S. Food and Drug Administration.
The company’s R&D combines materials science, device engineering, and translational biomedicine, leveraging expertise drawn from labs at Stanford University, Columbia University, University of Tokyo, and Weizmann Institute of Science. Core research areas include colloidal synthesis techniques influenced by protocols from Scripps Research, atomically precise fabrication methods reported at Lawrence Berkeley National Laboratory, and quantum dot and two-dimensional material work paralleling studies at University of Manchester. Multidisciplinary teams include former principal investigators from Johns Hopkins University, University of California, Berkeley, and Princeton University. CIME’s research portfolio lists projects on nanoparticle drug delivery systems comparable to efforts at Dana-Farber Cancer Institute and sensor platforms similar to work at National Institute of Standards and Technology. Collaborative grants have been submitted to agencies such as European Research Council and National Institutes of Health.
CIME operates cleanrooms and fabrication suites modeled after facilities at IMEC, Rutherford Appleton Laboratory, and KAUST with Class 10 to Class 1000 zones. Equipment includes electron microscopy systems derived from designs by Thermo Fisher Scientific and JEOL, atomic layer deposition systems analogous to those used at Tokyo Electron, and focused ion beam instruments reflecting standards from TESCAN. Biological containment labs follow specifications common to facilities at Wellcome Trust-funded centers and employ high-throughput screening instruments similar to platforms from PerkinElmer and Bio-Rad Laboratories. Pilot production lines have been located in industrial parks near Basel, Hsinchu Science Park, and Austin, enabling scale-up workflows in partnership with contract manufacturers such as Flex Ltd. and Foxconn.
CIME’s product lines include engineered lipid-polymer nanoparticles for targeted therapeutics comparable to platforms developed at Moderna and BioNTech, quantum dot inks for display technologies used alongside suppliers like Samsung Display and LG Display, and nanostructured electrodes for energy storage similar to innovations from Tesla and Panasonic. Other offerings comprise nanosensor arrays for environmental monitoring aligned with instrumentation from Siemens and Honeywell, as well as nano-enabled coatings deployed in aerospace projects with firms akin to Airbus and Boeing. In medical devices, CIME supplies components for diagnostic instruments used by clinical laboratories at Mayo Clinic and Cleveland Clinic. The company also commercializes research tools sold to academic labs resembling catalogs from Thermo Fisher Scientific and Agilent Technologies.
Strategic partnerships include university consortia with Imperial College London, joint ventures with industrial groups similar to ABB and Schneider Electric, and research alliances with national laboratories such as Argonne National Laboratory and Oak Ridge National Laboratory. CIME has entered commercialization agreements with pharmaceutical companies comparable to GlaxoSmithKline and AstraZeneca and materials supply contracts with semiconductor firms akin to TSMC. The company participates in standards and consortia forums alongside ISO, IEC, and regional innovation clusters like European Institute of Innovation and Technology.
Regulatory activities follow frameworks referenced by European Chemicals Agency and U.S. Environmental Protection Agency, with safety programs informed by international guidelines from World Health Organization and occupational health practices used in National Institute for Occupational Safety and Health. Environmental, health, and safety (EHS) systems mirror those implemented by large manufacturers such as Dow Chemical Company and BASF. Clinical translation adheres to pathways compatible with European Medicines Agency and U.S. Food and Drug Administration investigational procedures, including Good Manufacturing Practice analogues practiced at Novartis bioproduction sites.
CIME’s technologies have been cited in academic literature from institutions like Nature Research-published groups, Science-affiliated laboratories, and engineering departments at Carnegie Mellon University, influencing fields including nanomedicine, nanoelectronics, and energy storage. Controversies have included debates over nanoparticle environmental fate raised by researchers from University of California, Davis and regulatory scrutiny similar to public discussions involving Monsanto and nanomaterial governance in the EU. Ethical and safety critiques have been voiced by advocacy groups analogous to Greenpeace and policy analysts at Chatham House, prompting internal reviews and external audits by consulting firms resembling McKinsey & Company and KPMG.
Category:Nanotechnology companies